Literature DB >> 6252511

Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids.

W W Tourtellotte, R W Baumhefner, A R Potvin, B I Ma, J H Potvin, M Mendez, K Syndulko.   

Abstract

ACTH gel and corticosteroids were given to 28 clinically definite multiple sclerosis (MS) patients to determine whether de novo central nervous system (CNS) IgG synthesis (rate and cerebrospinal fluid [CSF] IgG oligoclonal bands) could be eradicated. The most effective treatments were ACTH gel and ACTH gel followed by prednisone, all 11 patients had a significant reduction in rate (p < 0.05), which became normal in eight patients (< 3.3 mg per day). In order of effectiveness, the other drugs used were: dexamethasone or prednisone given orally, and hydrocortisone administered intrathecally. For most treatments, reduction of the rate of CNS IgG synthesis occurred within days and persisted for months after cessation of treatment. The MS CNS immune reaction was not eradicated when IgG synthesis rate became normal, because CSF IgG oligoclonal bands persisted. None of the chronic progressive, severely disabled patients demonstrated significant change in neurologic function or persistent adverse effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252511     DOI: 10.1212/wnl.30.11.1155

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.

Authors:  D A Compston; N M Milligan; P J Hughes; J Gibbs; V McBroom; B P Morgan; A K Campbell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154

2.  Intrathecal methylprednisolone acetate in multiple sclerosis treatment: effect on the blood-CSF barrier and on the intrathecal IgG production.

Authors:  B Rocchelli; M Poloni; P Mazzarello; G Piccolo; M Delodovici; P Pinelli
Journal:  Ital J Neurol Sci       Date:  1982-07

Review 3.  Multiple sclerosis. Current concepts in management.

Authors:  B Giesser
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

4.  Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.

Authors:  W W Shih; R W Baumhefner; W W Tourtellotte; C M Haskell; E L Korn; J L Fahey
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

5.  Multiple sclerosis intra-blood-brain-barrier IgG synthesis: effect of pulse intravenous and intrathecal corticosteroids.

Authors:  R W Baumhefner; W W Tourtellotte; K Syndulko; A Staugaitis; P Shapshak
Journal:  Ital J Neurol Sci       Date:  1989-02

6.  Immunological treatment of multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

Review 7.  B-cell Therapy for Multiple Sclerosis: Entering an era.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

Review 8.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08

Review 9.  Melanocortins, Melanocortin Receptors and Multiple Sclerosis.

Authors:  Robert P Lisak; Joyce A Benjamins
Journal:  Brain Sci       Date:  2017-08-14

Review 10.  Compartmentalized intrathecal immunoglobulin synthesis during HIV infection - a model of chronic CNS inflammation?

Authors:  Mickael Bonnan; Bruno Barroso; Stéphanie Demasles; Elsa Krim; Raluca Marasescu; Marie Miquel
Journal:  J Neuroimmunol       Date:  2015-05-16       Impact factor: 3.478

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.